Polypeptide at 1-year low after guidance undershoots expectations

PolyPeptide AG

11/03/2025 11:25

** Shares in Polypeptide PPGN.S slump around 19% to their lowest price in a year after the Swiss maker of peptides for pharma and biotech companies gave FY guidance below consensus

** Polypeptide expects FY revenue growth of 10% to 20% and said its EBITDA margin is expected to continue to rise based on top-line growth for the year

** Baader Helvea says the implied range leaves current consensus of 411 million Swiss francs outside the given range

** "We believe the given guidance of 34-67 mln eur sales growth and unspecific EBITDA margin improvement can be seen as rather conservative," it adds

** The broker expects the stock to be rather weak over the next couple of days as the next catalyst might be postponed to H1 reporting after Monday's results

** The stock, which has lost 44.1% YTD including today's session, is on track for worst day since December 2022 if losses hold

 (Reporting by Ozan Ergenay)

 ((ozan.ergenay@thomsonreuters.com))